CD200 and neoplasm: The combination of metformin with immunotherapy, and lack of CD200 expression in either tumor (EMT6siCD200 tumors in WT mice) or host (CD200-/- mice) resulted in increased survival and prevention of lung metastasis compared with either immunotherapy or metformin treatment alone.